Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

Investigational New Drugs(2020)10.1007/s10637-020-00904-7Source: DataRank Database

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies is a research paper published in Investigational New Drugs (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.00)OA: closedTopics (42)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

P. A. Bradbury,P. M. Ellis,J. Laskin,C. Kollmannsberger,D. Hao

Live enrichment

PubMed:32020438 OpenAlex:https://openalex.org/W3005499534

Canadian Cancer Society Research Institute

Grant: 704970

FWCI

0.00

Citation Percentile

0.0%

closedLicense: https://www.springernature.com/gp/researchers/text-and-data-mining

publisherhttps://link.springer.com/content/pdf/10.1007/s10637-020-00904-7.pdf

publisherhttps://link.springer.com/article/10.1007/s10637-020-00904-7/fulltext.html

journalhttps://doi.org/10.1007/s10637-020-00904-7

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32020438

Fields of Study

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesPancreatic and Hepatic Oncology ResearchMedicineAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasms

MeSH Terms

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedNeoplasmsAntibodies, Monoclonal, Humanized

Keywords

TremelimumabDurvalumabTolerabilityMedicineAdverse effectInternal medicineCohortOncologyCancerNivolumabImmunotherapyIpilimumabPharmacokineticsClinical Trial

Sustainable Development Goals

SDG 0: Good health and well-being

A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

FAIR Checklist

Authors (19)

Funding (1 grants)

Impact

Open Access

Topics